GKGlaukos GKOS · NYSE
$177.03 +2.08% (+$3.60)
- Market cap
- $10.4B
- Enterprise value
- $10.4B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 17.0x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -9.6%
- Gross margin
- 79.1%
- Net margin
- -30.7%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.70
- Free float
- 96.0%
About the company
Glaukos Corporation is an American biotechnology company focused on the development and manufacture of innovative ophthalmic products. Founded in 1998, its headquarters are located in San Clemente, California. Glaukos specializes in the treatment of glaucoma and other eye diseases using new technologies, including implants and micro-surgical solutions. The company focuses on improving patients' quality of life through groundbreaking products and services that bring innovation to the field of ophthalmology.
Sector
Healthcare
Industry
Medical - Devices
CEO
Thomas William Burns
Employees
1,094
Headquarters
Aliso Viejo
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number